LOGIN  |  REGISTER
Recursion

SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference

September 05, 2024 | Last Trade: US$4.28 0.01 -0.23

DENVER, Sept. 05, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024 at 9:00 a.m. Eastern time. A webcast of the fireside chat will be available on the Events and Presentations section of the Company’s website.

Management is available for in-person and virtual one-on-one meetings throughout the conference being held September 9-11. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel.

About SeaStar Medical

SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Contact:

LHA Investor Relations
Jody Cain
(310) 691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB